A Phase I clinical trial testing an antibody that targets CD-352 is open for multiple myeloma patients who have had two lines of treatment including an immunomodulator and proteasome inhibitor. This study is in conjunction with Seattle Genetics and is open at 7 sites throughout the U.S. To learn more, listen to Dr. Damian Green discuss this study:

Learn more about this clinical trial here: CD-352 Clinical Trial